FilingSEC EDGAR8-K
Serina Therapeutics Advances SER-252 Phase 1b Study to Cohort 2
· SEC accepted
StagePhase 1b
Filing content
The independent Safety Monitoring Committee recommended advancing to Cohort 2 following a review of safety data from Cohort 1 of the SER-252 Phase 1b study. Topline data is expected in the first half of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…